Category: Semiconductors

Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

SBA Beats Expectations, Raises Guidance Once Again in the First Quarter

SBA Communications SBAC notched another strong firstquarter result, highlighted by better-than-expected earnings and another guidance upgrade. First-quarter revenues grew by 62% year over year to $313 million–roughly 4% above consensus. The growth was driven by a 64.1% increase in the firm’s tower base, which now stands at 17,539. Once again, however, SBA’s growth was in both quality and quantity. The firm was able to expand … Continue reading SBA Beats Expectations, Raises Guidance Once Again in the First Quarter

John MeadyLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

Sohu Posts Solid First-Quarter Results on Strong Top-Line Growth Across All Segments

Chinese Internet firm Sohu SOHU posted first-quarter revenue and earnings that slightly exceeded the firm’s guidance and our internal estimate, thanks to solid top-line growth across brand advertising, search, and gaming. Revenue grew by 36% year over year to $308 million (versus $299 million at the high end of guidance), while non-GAAP net income came in at $24 million (versus $21 million at the high … Continue reading Sohu Posts Solid First-Quarter Results on Strong Top-Line Growth Across All Segments

John MeadyLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

SCA Posts Steady 1Q Results and Sees Early Signs of Improving Construction Market

Swedish consumer goods company Svenska Cellulosa reported first-quarter results that largely tracked our longerterm expectations. SCA’s hygiene operations (personal care and tissue) were once again steady performers while the forest product division lagged as a result of still-weak European demand for paper and solid-wood products. After reviewing the results, we are maintaining our fair value estimate of SEK 136 per share and our no-moat rating. … Continue reading SCA Posts Steady 1Q Results and Sees Early Signs of Improving Construction Market

John MeadyLeave a comment
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

Trading Conditions in Europe Remain Soft in TNT’s First Quarter

TNT Express’ first-quarter consolidated revenue fell 4.5% from the same period last year (down 4% excluding foreign exchange). The decline was partly the result of softer Asia Pacific business, including sluggish export activity to Europe. Price competition and a continued mix shift to loweryielding shipments in Europe also contributed. Excluding foreign exchange, revenue was down 1% in the core Europe, Middle East, and Africa region, … Continue reading Trading Conditions in Europe Remain Soft in TNT’s First Quarter

John MeadyLeave a comment
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Saenz Steps Down as Santander CEO

On Monday, Banco Santander SAN announced that Alfredo Saenz has resigned as CEO ahead of a decision by Spanish regulators that would have effectively decided whether his criminal conviction should disallow him from working in banking. Until recently, Spain’s rules had prevented anyone with a criminal conviction from holding a senior position in banking. Saenz was convicted in 2009 of making false criminal acquisitions against … Continue reading Saenz Steps Down as Santander CEO

John MeadyLeave a comment
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

Media reports over the weekend suggested Valeant Pharmaceuticals VRX held merger discussions with Actavis ACT , which may now have stalled on financial considerations. Valeant had been signaling that it was seeking to pursue a large acquisition or a merger of equals, so the magnitude of the deal was not surprising, but we were a little surprised by the target. Overall, there may be enough … Continue reading Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

John MeadyLeave a comment